Mylan (NASDAQ:MYL) was upgraded by investment analysts at Leerink Swann from a “market perform” rating to an “outperform” rating in a research note issued on Thursday, MarketBeat Ratings reports. The brokerage currently has a $44.00 price target on the stock. Leerink Swann’s price objective points to a potential upside of 8.29% from the company’s previous close. Leerink Swann also issued estimates for Mylan’s Q1 2018 earnings at $0.92 EPS, Q2 2018 earnings at $1.22 EPS, Q3 2018 earnings at $1.46 EPS, FY2019 earnings at $5.95 EPS, FY2021 earnings at $7.15 EPS and FY2022 earnings at $8.10 EPS.
A number of other equities research analysts also recently commented on the stock. Zacks Investment Research downgraded shares of Mylan from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Citigroup restated a “buy” rating and issued a $58.00 price objective (up previously from $48.00) on shares of Mylan in a research report on Thursday, January 4th. Wells Fargo set a $43.00 price objective on shares of Mylan and gave the company a “hold” rating in a research report on Thursday, January 18th. TheStreet upgraded shares of Mylan from a “c” rating to a “b-” rating in a research report on Wednesday, January 17th. Finally, JPMorgan Chase set a $53.00 price objective on shares of Mylan and gave the company a “buy” rating in a research report on Friday, February 16th. Eight research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $47.02.
NASDAQ MYL opened at $40.63 on Thursday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.73 and a current ratio of 1.13. Mylan has a 52-week low of $29.39 and a 52-week high of $47.82. The stock has a market cap of $20,792.03, a P/E ratio of 8.91, a P/E/G ratio of 1.28 and a beta of 1.34.
In other news, Director Robert J. Coury sold 150,000 shares of Mylan stock in a transaction that occurred on Friday, March 2nd. The shares were sold at an average price of $40.10, for a total transaction of $6,015,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Rajiv Malik sold 50,000 shares of Mylan stock in a transaction that occurred on Friday, March 2nd. The shares were sold at an average price of $40.91, for a total transaction of $2,045,500.00. Following the sale, the president now owns 503,751 shares of the company’s stock, valued at $20,608,453.41. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 269,287 shares of company stock valued at $11,034,960. Insiders own 0.69% of the company’s stock.
Several hedge funds have recently bought and sold shares of MYL. Rational Advisors LLC purchased a new position in shares of Mylan during the 4th quarter worth approximately $190,000. First Personal Financial Services increased its stake in shares of Mylan by 77.1% during the 4th quarter. First Personal Financial Services now owns 4,839 shares of the company’s stock worth $205,000 after purchasing an additional 2,106 shares in the last quarter. Lombard Odier Asset Management Europe Ltd purchased a new position in shares of Mylan during the 4th quarter worth approximately $209,000. Mycio Wealth Partners LLC purchased a new position in shares of Mylan during the 4th quarter worth approximately $212,000. Finally, Advisor Partners LLC purchased a new position in shares of Mylan during the 4th quarter worth approximately $214,000. Institutional investors own 84.54% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Mylan (MYL) Upgraded to “Outperform” at Leerink Swann” was originally reported by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://dakotafinancialnews.com/2018/04/14/mylan-myl-upgraded-to-outperform-at-leerink-swann.html.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.